Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05916248 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05916248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05916248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pembrolizumab in Patients With Advanced Solid Tumors
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 20, 2023
Completion date
December 30, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor